Blood Pressure Tech Floods the Market After FDA Relaxes Wearables Oversight

AI justification

FDA's relaxation of oversight enables unvalidated tech to flood market, risking public health harms. | The FDA's relaxation of oversight for wellness wearables prioritizes market expansion and innovation over patient safety and evidence-based healthcare. While it may reduce regulatory costs, the flood of unvalidated blood pressure tech poses significant risks to public health, including potential misdiagnosis and harm. The net ethical judgment is negative due to the high magnitude of potential h